Rafael (NYSE:RFL – Get Free Report) and vTv Therapeutics (NASDAQ:VTVT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Insider and Institutional Ownership
11.3% of Rafael shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Rafael and vTv Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rafael | -3,321.74% | -41.27% | -35.32% |
| vTv Therapeutics | N/A | -6.27% | -5.06% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rafael | 1 | 0 | 0 | 0 | 1.00 |
| vTv Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
vTv Therapeutics has a consensus price target of $55.83, indicating a potential upside of 102.88%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than Rafael.
Volatility and Risk
Rafael has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.
Valuation & Earnings
This table compares Rafael and vTv Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rafael | $920,000.00 | 80.20 | -$30.52 million | ($0.68) | -2.09 |
| vTv Therapeutics | $36.84 million | 2.94 | -$26.97 million | ($1.06) | -25.96 |
vTv Therapeutics has higher revenue and earnings than Rafael. vTv Therapeutics is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.
Summary
vTv Therapeutics beats Rafael on 10 of the 15 factors compared between the two stocks.
About Rafael
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
About vTv Therapeutics
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
